Skip to main content

Current therapies for chronic hepatitis C

Publication ,  Journal Article
Patel, K; McHurtchinson, JG
Published in: SENDROM
July 1, 2004

Treatment options for chronic HCV infection have evolved significantly over the last few years, and current therapy with pegylated interferon and ribavirin is effective in 50% to 60% of patients with previously untreated infection. Although there is some encouraging progress in new antiviral drug development for hepatitis C, it will be several years before any of these novel compounds are available in clinical practice. In the interim, pegylated interferon and ribavirin remain the cornerstone of therapy. Healthcare providers have an important role in educating and selecting appropriate patients for therapy, recognizing common side effects, establishing a team approach to the management of chronic HCV infection, and keeping abreast of changes in treatment guidelines.

Duke Scholars

Published In

SENDROM

ISSN

1016-5134

Publication Date

July 1, 2004

Volume

16

Issue

7

Start / End Page

20 / 27

Related Subject Headings

  • General & Internal Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, K., & McHurtchinson, J. G. (2004). Current therapies for chronic hepatitis C. SENDROM, 16(7), 20–27.
Patel, K., and J. G. McHurtchinson. “Current therapies for chronic hepatitis C.” SENDROM 16, no. 7 (July 1, 2004): 20–27.
Patel K, McHurtchinson JG. Current therapies for chronic hepatitis C. SENDROM. 2004 Jul 1;16(7):20–7.
Patel, K., and J. G. McHurtchinson. “Current therapies for chronic hepatitis C.” SENDROM, vol. 16, no. 7, July 2004, pp. 20–27.
Patel K, McHurtchinson JG. Current therapies for chronic hepatitis C. SENDROM. 2004 Jul 1;16(7):20–27.

Published In

SENDROM

ISSN

1016-5134

Publication Date

July 1, 2004

Volume

16

Issue

7

Start / End Page

20 / 27

Related Subject Headings

  • General & Internal Medicine